DNA repair drugs play a vital role in treating DNA damages diseases like cancer and neurological disorders. They help repair damaged DNA which can significantly reduce the risk of mutations and development of serious diseases.
The global DNA Repair Drugs Market is estimated to be valued at US$ 6.28 Bn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the DNA repair drugs market is the development of drugs targeting multiple DNA repair pathways involved in cancer. Targeting a single DNA repair pathway has not shown promising results in clinical trials. Most late-stage cancers develop resistance to therapies over time by activating alternative repair pathways. Researchers are now developing drugs that can simultaneously block two or more DNA repair mechanisms used by cancer cells to develop resistance and promote tumor growth. For instance, drugs combining PARP and ATR inhibitors are being evaluated in clinical trials with encouraging results. Such multi-targeted therapy approaches are expected to transform the treatment of advanced cancers in the coming years.
Strength: DNA repair drugs help repair damaged DNA and prevent further damage. They can effectively treat various types of cancer.
Weakness: DNA repair drugs exhibit harmful side effects such as nausea, vomiting, hair loss etc. They may also interfere with normal DNA repair processes.
Opportunity: Rising cancer incidence worldwide provides huge market potential for DNA repair drugs. Emerging technologies to develop more targetted and personalized DNA repair therapies.
Threats: Stiff competition from other cancer treatment options like targeted therapy and immunotherapy. Long drug development cycles and high R&D costs.
The global DNA repair drugs market size is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing cancer prevalence worldwide. The market size for 2023 is estimated to be US$ 6.28 billion.
Regional analysis: North America dominated the global market in 2023 and is expected to remain the highest revenue generating region throughout the forecast period. This is attributed to rising healthcare expenditure, well developed healthcare infrastructure and growing awareness about DNA repair drugs. Asia Pacific is anticipated to be the fastest growing region owing to huge patient population, improving access to healthcare and rising focus of international players.
Key players operating in the DNA repair drugs market are AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Merck KGAA, Novartis AG, Pfizer Inc., and Sanofi S.A. Companies are focusing on strategic collaborations and new product launches to strengthen their market position.